<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Focus Middle East and India &#187; EMEA</title>
	<atom:link href="http://www.focus-mei.de/category/development-regulatory-planning/emea/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.focus-mei.de</link>
	<description>Indian pharma excellence for Western Markets!</description>
	<lastBuildDate>Mon, 08 Dec 2008 20:24:43 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Free documentation: Success factors to achieve EU pharma product registration</title>
		<link>http://www.focus-mei.de/focus-mei-current-information/free-documentation-success-factors-pharma-product-registration/</link>
		<comments>http://www.focus-mei.de/focus-mei-current-information/free-documentation-success-factors-pharma-product-registration/#comments</comments>
		<pubDate>Tue, 07 Oct 2008 08:21:05 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[EMEA]]></category>
		<category><![CDATA[FOCUS-MEI current information]]></category>

		<guid isPermaLink="false">http://www.focus-mei.de/?p=46</guid>
		<description><![CDATA[Western markets offer significant business opportunities for Indian pharmaceuticals. Thus, Indian pharma companies look for smart approaches towards product registration in western markets, such as in the EU or in the US, via EMEA or FDA, respectively.
FOCUS Clinical Drug Development GmbH (FOCUS-CDD) has many years of successful experience with EMEA and FDA submissions and registrations. [...]]]></description>
			<content:encoded><![CDATA[<p>Western markets offer significant business opportunities for Indian pharmaceuticals. Thus, Indian pharma companies look for smart approaches towards product registration in western markets, such as in the EU or in the US, via EMEA or FDA, respectively.</p>
<p>FOCUS Clinical Drug Development GmbH (FOCUS-CDD) has many years of successful experience with EMEA and FDA submissions and registrations. Through it&#8217;s Dubai-based subsidiary &quot;FOCUS Middle East &amp; India&quot; this competence is offered to the Indian pharmaceutical industry. A particular strength of FOCUS-MEI is it&#8217;s international staff that comprises German and Indian drug development experts who are familiar wih both industry cultures.</p>
<p>The experts at FOCUS-MEI have compiled the documenation <strong><em>&quot;Major success factors to achieve&nbsp;EU pharmaceutical product registration for Indian pharmaceutical products&quot;</em></strong>.</p>
<p>You can order&nbsp;&nbsp;your complimentary copy by contacting Dr. Chandrashekhar via chandrashekhar@avicennapharma.com.&nbsp;</p>
]]></content:encoded>
			<wfw:commentRss>http://www.focus-mei.de/focus-mei-current-information/free-documentation-success-factors-pharma-product-registration/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
